147 Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control

147 Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control

Bibliographic Details
Main Authors:	Yan Zhang, Elvira Argus, Maximilian Richter, Yening Tan, Min Tong, Eric Ostertag, Julia Coronella, Devon Shedlock, Jing Qiu, Stacey Cranert, Hubert Tseng, Karl Marquez, Benjamin Cho, Christine Domingo, Leslie Weiss, Jessica Sparks
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

120 P-MUC1C-ALLO1: An allogeneic car-t for multiple solid tumor indications
by: Yan Zhang, et al.
Published: (2020-11-01)

123 P-MUC1C-ALLO1: A fully allogeneic stem cell memory T cell (TSCM) CAR-T therapy with broad potential in solid tumor
by: Yan Zhang, et al.
Published: (2021-11-01)

Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells
by: Blair B. Madison, et al.
Published: (2022-09-01)

135 Identification and characterization of an allogeneic iNKT-CAR targeting BCMA
by: Xavier Michelet, et al.
Published: (2021-11-01)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01)

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
by: Ying Wang, et al.
Published: (2022-09-01)

Decoding plasma cell maturation dynamics with BCMA
by: Sebastian R. Schulz, et al.
Published: (2025-03-01)

Expression of TNF-α, April and BCMA in Behcet’s Disease
by: Olfat G. Shaker, et al.
Published: (2014-01-01)

Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
by: Tapan K. Bera
Published: (2020-09-01)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
by: Rahul Banerjee, et al.
Published: (2022-11-01)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
by: Estefanía García-Guerrero, et al.
Published: (2022-09-01)

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
by: Andrew J. Yee
Published: (2024-07-01)

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
by: Karthik Nath, et al.
Published: (2024-05-01)

High antigen density of BCMA: friend or foe to CAR T cells?
by: Marcela V Maus, et al.
Published: (2022-09-01)

Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01)

An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery
by: Silvia Catuogno, et al.
Published: (2019-12-01)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
by: Larysa Sanchez, et al.
Published: (2021-01-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

Therapeutic effect of CAR-γδT cells targeting at BCMA in multiple myeloma
by: LI Yinghui, XU Yi, ZHANG Jianmin, CHEN Hui, HE Wei
Published: (2024-06-01)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
by: Martin Vogel, et al.
Published: (2023-05-01)

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy
by: Nausheen Ahmed, et al.
Published: (2023-08-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
by: Kevin Miller, et al.
Published: (2024-05-01)

Anti‐BCMA Immuno‐NanoPET Radiotracers for Improved Detection of Multiple Myeloma
by: Thomas, Eloise, et al.
Published: (2022)

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
by: Mahmoud R. Gaballa, et al.
Published: (2025-03-01)

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies
by: Adam D. Cohen, et al.
Published: (2019-08-01)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
by: Ortal Harush, et al.
Published: (2022-03-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
by: Borja Puertas, et al.
Published: (2022-03-01)

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA
by: Felix Oh, et al.
Published: (2023-06-01)

Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment
by: Minchuan Zhang, et al.
Published: (2024-11-01)

BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy
by: Wei Zhang, et al.
Published: (2024-08-01)

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
by: Xiang Zhou, et al.
Published: (2022-10-01)

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1
by: Irene Cattaneo, et al.
Published: (2024-02-01)

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
by: U. Munawar, et al.
Published: (2023-05-01)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
by: Abhinava K. Mishra, et al.
Published: (2023-11-01)

BCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell Stemness
by: Vasiliki Pelekanou, et al.
Published: (2018-08-01)